[ad_1]
Merck (MRK) did a lot of things in cancer immunotherapy, probably more than one of his competitors. But the clinical debut of a new immune-stimulating drug from its early stage cancer pipeline on Saturday suggests Merck is ignoring the harsh lesson of its biggest mistake.
The new drug Merck, called MK-1454, shows no evidence that it can kill cancer cells when it is injected alone to patients, as monotherapy. But when MK-1454 was used in combination with Merck's Keytruda checkpoint inhibitor, tumors in a small number of patients decreased.
Unlock this item by subscribing to STAT Plus. Try it for free for 30 days!
TO START
What is it?
STAT Plus is a premium subscription offering scalable biopharmaceutical market coverage and in-depth scientific reports emanating from a team with decades of experience in the industry.
What is included?
- Authoritative coverage and biopharmaceutical analysis, interviews with industry pioneers, policy analysis and early review of advanced labs and early stage research
- Subscriber Networking Events and Group Discussions Across the Country
- Live monthly subscriber discussions with our reporters and experts in the field
- Discounted tickets for industry events and early access to industry reports
[ad_2]
Source link
